5 completed. 3 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 3 |
| Phase 2 | 2 | Completed 2 |
Follow AZD-8871: new trials by email Literature Review of AZD-8871 trials Research Report on AZD-8871
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Single Inhalation Dose Study to Assess Efficacy, Pharmacokinetics (PK), Safety and Tolerability of AZD8871 in Patients With Long-term Lung Diseases. AZD8871, Anoro® Ellipta® - Chronic Obstructive Pulmonary Disease | Phase 2 | Completed | AstraZeneca | 73 | 2018-10-10 | 2020-12-17 |
| Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of AZD8871 in Healthy Male Japanese Subjects AZD8871, Placebo - Chronic Obstructive Pulmonary Disease - COPD | Phase 1 | Completed | AstraZeneca | 25 | 2017-06-19 | 2017-10-25 |
| Efficacy, Pharmacokinetics (PK), Safety and Tolerability Study of Inhaled AZD8871 AZD8871 100 µg, AZD8871 600 µg, Placebo - Chronic Obstructive Pulmonary Disease COPD | Phase 2 | Completed | AstraZeneca | 42 | 2016-12-15 | 2019-06-18 |
| Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of AZD8871 in Healthy Subjects AZD8871, Placebo - Chronic Obstructive Pulmonary Disease | Phase 1 | Completed | AstraZeneca | 24 | 2016-06-22 | 2019-02-15 |
| Two-part Safety, Tolerability, Pharmacodynamic and -Kinetic Study of Inhaled AZD8871 in Asthmatic and COPD Subjects Dose 1, AZD8871 50 μg (Part 1), Dose 2, AZD8871 100 μg (Part 1), Dose 3, AZD8871 300 μg (Part 1) - Asthma (Part 1), COPD (Part 2) | Phase 1 | Completed | AstraZeneca | 134 | 2015-10-01 | 2018-11-08 |
Pulmonary Disease, Chronic Obstructive (5) · Asthma (3) · Emphysema (1)
AstraZeneca (5)
United Kingdom (5) · Germany (2)
Muna Albayaty, MBChB, MSc, MFPM (2) · Dave Singh, Prof (1) · Dave Singh, Prof. (1) · Muna Albayaty, MBChB, MSc,MFPM (1) · Rainard Fuhr, Dr (1)
PMID 32907575, PMID 32907566, PMID 32907576, PMID 34503985
2015 (1), 2017 (1)